X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will be used for the development of company's portfolio of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine), which is under investigation for the treatment of PTSD and social anxiety in autistic adults.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 19, 2024
Details:
The net proceeds will be used for the development of company's portfolio of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine), which is under investigation for the treatment of PTSD and social anxiety in autistic adults.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: ALA-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 10, 2024
Details:
MDMA (Midomafetamine) is a ring-substituted amphetamine analog with reinforcing psychoactive effects. It is a 5-HT2A receptor agonist, which is under development for the treatment of posttraumatic stress disorder.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2024
Details:
The proceeds will support regulatory and pre-launch activities for investigational MDMA-assisted therapy, an investigational modality being studied using a combination of MDMA, psychological intervention and other supportive services for post-traumatic stress disorder.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA-assisted Therapy
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Helena
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 05, 2024
Details:
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic, psychoactive drug with a chemical structure similar to the stimulant methamphetamine and the hallucinogen mescaline being developed the treatment of for PTSD.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
MDMA (3,4-methylenedioxymethamphetamine) is a 5-HT2A receptor agonist, small molecule drug candidate, which is currently being evaluated for the treatment of patients with Post-traumatic stress disorder.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic, psychoactive drug with a chemical structure similar to the stimulant methamphetamine and the hallucinogen mescaline.
Lead Product(s): Midomafetamine
Therapeutic Area: Oncology Product Name: MDMA
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
MDMA-AT (3,4-methylenedioxymethamphetamine) mainly acts as a releaser of serotonin (5-HT) and noradrenaline, and to a lesser extent also of dopamine, which is investigated for the treatment of Posttraumatic Stress Disorder.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA-AT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
The grant provides MAPS with vital mission support as it enters the final stages of the drug development process for MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for the treatment of PTSD.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Steven & Alexandra Cohen Foundation
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 22, 2023
Details:
MYCO-006—MDMA-derived short-acting drug analogs (3,4-methylenedioxymethamphetamine) are designed for treating various conditions, including anxiety and pain.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MYCO-006
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
3,4-methylenedioxymethamphetamine (MDMA microneedle patch) mainly acts as a releaser of serotonin (5-HT) and noradrenaline, and to a lesser extent also of dopamine, it is being developed for the treatment of for mental health and abuse disorders.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
3,4-methylenedioxymethamphetamine acts as a releaser of 5-HT and noradrenaline, and to a lesser extent also of dopamine. It is a potent empathogen-entactogen with stimulant properties primarily used for recreational purposes.
Lead Product(s): Midomafetamine,Ibogaine Hydrochloride,Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects.
Lead Product(s): Psilocybine,Midomafetamine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
Under the terms of the collaboration, Revive Therapeutics will evaluate the delivery of 3,4-Methylenedioxymethamphetamine (MDMA) using PharmaTher’s novel microneedle patch (MN-Patch) delivery technology.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaTher
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 03, 2023
Details:
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic, psychoactive drug with a chemical structure similar to the stimulant methamphetamine and the hallucinogen mescaline.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
The Phase 1 study is designed to evaluate the safety and tolerability of EMP-01 (3,4-methylenedioxymethamphetamine) in participants, as well as assess the usability and acceptability of the IDEA-1 app in delivering “set and setting” content to participants.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: EMP-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
The agreement will focus on investigating a market-ready proprietary formulation and optimized delivery route for 3,4-methylenedioxy-methamphetamine (MDMA) using Catalent's proprietary Zydis® orally disintegrating tablet (ODT) technology.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Awakn Life Sciences Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 12, 2022
Details:
MDMA, which is a racemic mixture of two structurally unique stereoisomers, R(-) and S(+), is currently in development for the treatment of Post-traumatic Stress Disorder (PTSD), and has demonstrated statistically significant positive results in a pivotal Phase 3 trial.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
In this first Phase 3 trial of any psychedelic-assisted therapy, participants who received MDMA-assisted therapy reported a significant reduction in PTSD symptoms vs those who received placebo with therapy, achieving the prespecified primary endpoint for the trial.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MDMA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
